AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15563434 — intervention group
Group type: EXPERIMENTAL
Intervention: 74‐item semi‐quantitative food frequency questionnaire (FFQ)
Number of subjects: 159
Study 15563434 — intervention group
Group type: COMPARATOR
Intervention: 3‐day weighed food records (WFR)
Number of subjects: 159
Study 11176181 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical fiber scope
Number of subjects: 30
Study 11176181 — intervention group
Group type: COMPARATOR
Intervention: Chest roentgenogram (CXR)
Number of subjects: 30
Study 9541091 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 47
Study 9541091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 8006243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 89
Study 8006243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 2801589 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplement (1500 mg Ca/d)
Number of subjects: 169
Study 2801589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 4425917 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 4425917 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 6
Study 4425917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31230343 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with residual PVOI ≥ 5%
Number of subjects: 371
Study 31230343 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 371
Study 31230343 — intervention group
Group type: EXPERIMENTAL
Intervention: PVOI ≥ 25% at PE diagnosis
Number of subjects: 371
Study 31230343 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated factor VIII
Number of subjects: 371
Study 31230343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic respiratory disease
Number of subjects: 371
Study 31230343 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥ 1 of these factors
Number of subjects: 371
Study 28376732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy consumption of vegetables on sandwiches
Number of subjects: 575
Study 28376732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy consumption of other vegetables
Number of subjects: 575
Study 28376732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy consumption of fruits (apples, pears, oranges or bananas)
Number of subjects: 575
Study 28376732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy consumption of other fruits and berries
Number of subjects: 575
Study 28376732 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy consumption of fruits and vegetables as snacks
Number of subjects: 575
Study 28376732 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily consumption of vegetables with dinner
Number of subjects: 575
Study 28376732 — intervention group
Group type: EXPERIMENTAL
Intervention: Older women
Number of subjects: 575
Study 23048047 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 54
Study 23048047 — intervention group
Group type: COMPARATOR
Intervention: Negative feedback
Number of subjects: 54
Study 23048047 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 54
Study 23647285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 178
Study 23647285 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant Medications (ADMs)
Number of subjects: 178
Study 23350342 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate and calcitonin
Number of subjects: 0
Study 23350342 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) 1-84
Number of subjects: 0
Study 19482956 — intervention group
Group type: COMPARATOR
Intervention: Standard oral care with 0.12% chlorhexidine digluconate
Number of subjects: 147
Study 19482956 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral care plus electric toothbrushing
Number of subjects: 147
Study 16998134 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach - caries removed by dental burs, filled with light-cured resin-modified glass ionomer
Number of subjects: 103
Study 16998134 — intervention group
Group type: EXPERIMENTAL
Intervention: ART approach - caries removed by hand instruments, filled with chemically cured high-strength glass ionomer
Number of subjects: 103
Study 12441260 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC (vincristine, doxorubicin, cyclophosphamide) and VIAc (vincristine, ifosfamide, actinomycin) chemotherapy regimen
Number of subjects: 157
Study 12441260 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery, surgery+radiotherapy, or radiotherapy only as local treatment
Number of subjects: 157
Study 12441260 — intervention group
Group type: COMPARATOR
Intervention: Previous studies with three-drug VAC regimen (REA-1) and four-drug VACAc regimen (REA-2 and REN-1)
Number of subjects: 157
Study 12441260 — intervention group
Group type: COMPARATOR
Intervention: Previous study (REN-2) with a six-drug regimen
Number of subjects: 157
Study 10515844 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF plus sodium stibogluconate (20 mg/kg‐1/day‐1 for 20 days)
Number of subjects: 20
Study 10515844 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) plus sodium stibogluconate (20 mg/kg‐1/day‐1 for 20 days)
Number of subjects: 20
Study 7722140 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated patients with chronic severe anemia
Number of subjects: 14
Study 7722140 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 14
Study 7722140 — intervention group
Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion in anemic patients
Number of subjects: 14
Study 7722140 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-mononmethyl-L-arginine (16 mumol/min) in untreated patients
Number of subjects: 14
Study 7722140 — intervention group
Group type: COMPARATOR
Intervention: NG-mononmethyl-L-arginine (16 mumol/min) in control subjects
Number of subjects: 14
Study 7722140 — intervention group
Group type: EXPERIMENTAL
Intervention: NG-mononmethyl-L-arginine (16 mumol/min) in treated patients
Number of subjects: 14
Study 1723464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (2 x 10 mg daily)
Number of subjects: 28
Study 1723464 — intervention group
Group type: COMPARATOR
Intervention: No nitrendipine
Number of subjects: 28
Study 7347558 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 300 mg/day
Number of subjects: 248
Study 7347558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine 300 mg/day
Number of subjects: 248
Study 7347558 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/day
Number of subjects: 248
Study 7347558 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine 200 mg/day
Number of subjects: 248
Study 7347558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 6746357 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (first 10 Gy in five consecutive daily fractions)
Number of subjects: 52
Study 29287875 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation
Number of subjects: 101
Study 29287875 — intervention group
Group type: COMPARATOR
Intervention: Microdebrider (ME)
Number of subjects: 101
Study 27930529 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (TIVA group)
Number of subjects: 60
Study 27930529 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (SEVO group)
Number of subjects: 60
Study 24584549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (single oral dose)
Number of subjects: 0
Study 24584549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21770837 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal stimulation protocol (5 days CC 100 mg/day then 150 IU uFSH on cycle day 9)
Number of subjects: 113
Study 21770837 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) only
Number of subjects: 113
Study 19952860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine coadministered with MMR vaccine
Number of subjects: 0
Study 19952860 — intervention group
Group type: COMPARATOR
Intervention: MMR vaccine alone
Number of subjects: 0
Study 18850388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediated intervention (short film)
Number of subjects: 0
Study 18850388 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 15763054 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin administered intravenously at a dosage of 250 mug/h for consecutive 72 hours
Number of subjects: 39
Study 15763054 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with non-surgical integrated traditional Chinese and Western medicine
Number of subjects: 39
Study 12428174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation (25 mg/day) for 45 days
Number of subjects: 0
Study 12428174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10894073 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent-learning materials for teaching chest radiology (12 cases)
Number of subjects: 58
Study 10894073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no independent-learning materials)
Number of subjects: 58
Study 7781401 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with etoposide/cisplatin
Number of subjects: 0
Study 7781401 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy/chest irradiation
Number of subjects: 0
Study 7781401 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 7781401 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery as sole treatment
Number of subjects: 0
Study 7781401 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 0
Study 2340741 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 U heparin/mL
Number of subjects: 104
Study 2340741 — intervention group
Group type: COMPARATOR
Intervention: 0.25 U heparin/mL
Number of subjects: 104
Study 6459045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 0
Study 6459045 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30843921 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR-Bio vaccine
Number of subjects: 0
Study 30843921 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine
Number of subjects: 0
Study 28028150 — intervention group
Group type: EXPERIMENTAL
Intervention: SST+tPA
Number of subjects: 0
Study 25747582 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG STV
Number of subjects: 503
Study 25747582 — intervention group
Group type: EXPERIMENTAL
Intervention: DV p95
Number of subjects: 503
Study 25747582 — intervention group
Group type: EXPERIMENTAL
Intervention: DV no A
Number of subjects: 503
Study 25747582 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ductus changes (DV no A)
Number of subjects: 503
Study 24437236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (suprax solutab) 400 mg 1 time a day for 7 days
Number of subjects: 112
Study 24437236 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (amoksiklav) 625 mg 3 times a day for 7 days
Number of subjects: 112
Study 24437236 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 112
Study 22225439 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert concept map advance organizer
Number of subjects: 46
Study 22225439 — intervention group
Group type: COMPARATOR
Intervention: Control lecture
Number of subjects: 46
Study 19363013 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative care (Res-Care) intervention
Number of subjects: 556
Study 19363013 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 556
Study 17513537 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical morphine sulphate
Number of subjects: 49
Study 17513537 — intervention group
Group type: COMPARATOR
Intervention: Intrasite gel and water (placebo)
Number of subjects: 49
Study 17513537 — intervention group
Group type: COMPARATOR
Intervention: Jelonet dressing (control)
Number of subjects: 49
Study 15309452 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE FB (low-digestible carbohydrate) at a level of 100 g DM/d
Number of subjects: 10
Study 15309452 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 10
Study 12058086 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor wrist-to-palm conduction velocity (W-P MCV)
Number of subjects: 116
Study 12058086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory wrist-to-palm conduction velocity (W-P SCV)
Number of subjects: 116
Study 12058086 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L-INT (median-second lumbrical and ulnar-interossei muscles)
Number of subjects: 116
Study 12058086 — intervention group
Group type: EXPERIMENTAL
Intervention: M-U (median-thenar and ulnar-hypothenar muscles)
Number of subjects: 116
Study 12058086 — intervention group
Group type: EXPERIMENTAL
Intervention: Median motor distal latency (MDL)
Number of subjects: 116
Study 12058086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory distal latency
Number of subjects: 116
Study 12058086 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of W-P MCV and W-P SCV
Number of subjects: 116
Study 10418043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (ACV) secondary prophylaxis, mean posology 2,400 mg (1,600‐4,000) per day, during mean 10 months (median 4 months)
Number of subjects: 39
Study 10418043 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 39
Study 7574048 — intervention group
Group type: EXPERIMENTAL
Intervention: PCHE equivalent to activity present in 2.5, 5, 7.5, 15, or 25 ml/kg of human plasma
Number of subjects: 48
Study 7574048 — intervention group
Group type: EXPERIMENTAL
Intervention: PCHE equivalent to activity present in 25 ml/kg of human plasma
Number of subjects: 48
Study 7574048 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery group (8 subjects)
Number of subjects: 48
Study 2040990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic thermometer measurements
Number of subjects: 20
Study 2040990 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter measurements
Number of subjects: 20
Study 6455096 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 14
Study 6455096 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 14
Study 6455096 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 14
Study 6455096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31863599 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 88
Study 31863599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 30379832 — intervention group
Group type: EXPERIMENTAL
Intervention: BioNumerics software for MIRU-VNTR typing
Number of subjects: 272
Study 30379832 — intervention group
Group type: COMPARATOR
Intervention: GeneMapper software for MIRU-VNTR typing
Number of subjects: 272
Study 27779456 — intervention group
Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg/day
Number of subjects: 61
Study 27779456 — intervention group
Group type: COMPARATOR
Intervention: Control group (other antihypertensive treatments)
Number of subjects: 61
Study 27779456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Lercanidipine and Control)
Number of subjects: 61
Study 24742399 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive marital assessments by men
Number of subjects: 1110
Study 24742399 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive appraisals
Number of subjects: 1110
Study 24742399 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative marital profile
Number of subjects: 1110
Study 22251379 — intervention group
Group type: EXPERIMENTAL
Intervention: Inductive reasoning training supplemented by weekly crossword and Sudoku puzzles
Number of subjects: 0
Study 22251379 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 20207663 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss framed screening invitations
Number of subjects: 116
Study 20207663 — intervention group
Group type: COMPARATOR
Intervention: Gain framed screening invitations
Number of subjects: 116
Study 16904652 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 15
Study 16904652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16298062 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS-S (Pain Catastrophizing Scale - Significant Other)
Number of subjects: 111
Study 16298062 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS-S
Number of subjects: 111
Study 16298062 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of catastrophizing in both spouses
Number of subjects: 111
Study 14650462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochrane reviews in pain and palliative care
Number of subjects: 100
Study 9842763 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimenter-generated imagery
Number of subjects: 0
Study 9842763 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject-generated imagery
Number of subjects: 0
Study 9842763 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of Loci
Number of subjects: 0
Study 9842763 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery mnemonics
Number of subjects: 0
Study 7986467 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg, equivalent to 2 to 3 cups of coffee)
Number of subjects: 30
Study 2574191 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 2574191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30320888 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-shaped fasciotome
Number of subjects: 20
Study 30320888 — intervention group
Group type: COMPARATOR
Intervention: Metzenbaum scissors
Number of subjects: 20
Study 29200446 — intervention group
Group type: EXPERIMENTAL
Intervention: profession‐specific educational intervention
Number of subjects: 27
Study 29200446 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 27
Study 26296647 — intervention group
Group type: EXPERIMENTAL
Intervention: Land or water-based exercise
Number of subjects: 50
Study 24175685 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-explanation prompts
Number of subjects: 69
Study 24175685 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional practice
Number of subjects: 69
Study 24175685 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 69
Study 21593648 — intervention group
Group type: EXPERIMENTAL
Intervention: Study formula alone
Number of subjects: 190
Study 21593648 — intervention group
Group type: EXPERIMENTAL
Intervention: Study formula with BL999
Number of subjects: 190
Study 21593648 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 190
Study 21593648 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 190
Study 21593648 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota profile in study formulae and breast-fed infants
Number of subjects: 190
Study 21593648 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth measurements, digestive tolerance, and adverse events
Number of subjects: 190
Study 18433403 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus paclitaxel (GT)
Number of subjects: 336
Study 18433403 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (T)
Number of subjects: 336
Study 17087671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health education programmes
Number of subjects: 14
Study 12856494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical vagus nerve stimulation (VNS); duration not specified.
Number of subjects: 0
Study 12856494 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment; duration not specified.
Number of subjects: 0
Study 12856494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical vagus nerve stimulation (VNS); longer-term follow-up (1 year and 2 years).
Number of subjects: 0
Study 10862808 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg q.d., n = 11)
Number of subjects: 20
Study 10862808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 20
Study 10862808 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram (250 mg q.d.)
Number of subjects: 20
Study 10862808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9195495 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus DBD (200 mg/m2 orally on Days 1-10 every five weeks)
Number of subjects: 238
Study 9195495 — intervention group
Group type: COMPARATOR
Intervention: RT plus BCNU (200 mg/m2 intravenously every seven weeks)
Number of subjects: 238
Study 8435205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for 18 months
Number of subjects: 359
Study 8435205 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for 6 months
Number of subjects: 359
Study 2892863 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 175
Study 2892863 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (30 mg)
Number of subjects: 175
Study 2892863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 30067600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir exposure
Number of subjects: 27
Study 30067600 — intervention group
Group type: COMPARATOR
Intervention: Unexposed to Tenofovir
Number of subjects: 27
Study 26073422 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical periodontal treatment
Number of subjects: 76
Study 26073422 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical periodontal treatment
Number of subjects: 76